WuXi Biologics (Cayman) Inc
HKEX:2269

Watchlist Manager
WuXi Biologics (Cayman) Inc Logo
WuXi Biologics (Cayman) Inc
HKEX:2269
Watchlist
Price: 17.46 HKD 0.46% Market Closed
Market Cap: 72.5B HKD
Have any thoughts about
WuXi Biologics (Cayman) Inc?
Write Note
WuXi Biologics (Cayman) Inc
/
Balance Sheet
/
Long-Term Debt

WuXi Biologics (Cayman) Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

WuXi Biologics (Cayman) Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
WuXi Biologics (Cayman) Inc
HKEX:2269
Long-Term Debt
¥3.5B
CAGR 3-Years
2%
CAGR 5-Years
74%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Long-Term Debt
¥4B
CAGR 3-Years
29%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Long-Term Debt
¥4.8B
CAGR 3-Years
1%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Long-Term Debt
¥791.6m
CAGR 3-Years
28%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Genscript Biotech Corp
HKEX:1548
Long-Term Debt
$351.1m
CAGR 3-Years
126%
CAGR 5-Years
125%
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Long-Term Debt
¥1.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi Biologics (Cayman) Inc
Glance View

Market Cap
72.5B HKD
Industry
Life Sciences Tools & Services

WuXi Biologics (Cayman) Inc. emerged from the bustling arena of global pharmaceuticals as a beacon of innovation and flexibility in the biologics manufacturing space. Founded in 2010, this Chinese firm quickly established itself as a key player by offering a comprehensive suite of services that span the entire biologics development process. The company's strategy revolves around its "Follow-the-Molecule" business model, characterized by a symbiotic partnership with clients from the early stages of drug discovery through clinical development and all the way to commercial manufacturing. This approach ensures not only seamless integration across different development stages but also cultivates long-term relationships with clients, including startups and large pharmaceutical giants. Utilizing state-of-the-art technologies and an expansive network of manufacturing facilities around the globe, WuXi Biologics has positioned itself as an indispensable partner for firms looking to bring new biologics to market swiftly and efficiently. The revenue model of WuXi Biologics hinges on its ability to offer flexible, customer-centric solutions in a highly demanding industry. Unlike traditional pharmaceutical companies that solely profit from drug sales, WuXi Biologics earns money by leveraging its Contract Development and Manufacturing Organization (CDMO) platform to provide end-to-end services. This includes process development, clinical trials, regulatory submissions, and commercial production. The company capitalizes on strategic partnerships and its burgeoning pipeline of projects, earning fees at each stage of the drug development cycle. By ensuring proprietary access to its advanced technologies and broad capabilities, WuXi Biologics not only supports its clients' needs but also fortifies its revenue streams via milestone payments, service fees, and long-term manufacturing contracts. Such a business model not only diversifies its income but also mitigates risks associated with drug development uncertainty, allowing the company to thrive in the competitive global healthcare market.

Intrinsic Value
32.47 HKD
Undervaluation 46%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is WuXi Biologics (Cayman) Inc's Long-Term Debt?
Long-Term Debt
3.5B CNY

Based on the financial report for Jun 30, 2024, WuXi Biologics (Cayman) Inc's Long-Term Debt amounts to 3.5B CNY.

What is WuXi Biologics (Cayman) Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
74%

Over the last year, the Long-Term Debt growth was -10%. The average annual Long-Term Debt growth rates for WuXi Biologics (Cayman) Inc have been 2% over the past three years , 74% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 211,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.